

3. McClhery SM, Scott KJ, Clarke SC. Clonal analysis of invasive pneumococcal isolates in Scotland and coverage of serotypes by licensed conjugate polysaccharide pneumococcal vaccine: possible implications for UK vaccine policy. *Eur J Clin Microbiol Infect Dis* 2005; 24: 262–267.
4. Byington C, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. *Pediatr Infect Dis J* 2006; 25: 250–254.
5. Obando I, Muñoz-Almagro C, Arroyo LA et al. Pediatric parapneumonic empyema, Spain. *Emerg Infect Dis* 2008; 14: 1390–1397.
6. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. *Clin Infect Dis* 2008; 46: 174–182.
7. Web de l'Estadística Oficial de Catalunya. Institut d'Estadística de Catalunya. Available at: <http://www.idescat.net> (accessed 25 May 2009).
8. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement. CLS document M100-S18. Wayne, PA: CLSI, 2008.
9. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of *Streptococcus pneumoniae* virulence factors in host respiratory colonization and disease. *Nat Rev Microbiol* 2008; 6: 288–301.
10. Obert C, Sublett J, Kaushal D et al. Identification of a candidate *Streptococcus pneumoniae* core genome and regions of diversity correlated with invasive pneumococcal disease. *Infect Immun* 2006; 74: 4766–4777.
11. Shivshankar P, Sanchez C, Rose LF, Orihuela CJ. The *Streptococcus pneumoniae* adhesin PsrP binds to keratin 10 on lung cells. *Mol Microbiol* 2009; 73: 663–679.
12. Muñoz-Almagro C, Selva L, Sanchez CJ et al. PsrP, a protective pneumococcal antigen, is highly prevalent in children with pneumonia and is strongly associated with clonal type. *Clin Vaccine Immunol* 2010; 17: 1672–1678.
13. Bruggemann AB, Spratt BG. Geographic distribution and clonal diversity of *Streptococcus pneumoniae* serotype 1 isolates. *J Clin Microbiol* 2003; 41: 4966–4970.
14. Gonzalez B, Hilten K, Kaplan S, Mason EO Jr, the US Pediatric Multicenter Pneumococcal Surveillance Study Group. Clonality of *Streptococcus pneumoniae* serotype 1 isolates from paediatric patients in the United States. *J Clin Microbiol* 2004; 42: 2810–2812.
15. Muñoz-Almagro C, Esteva C, de Sevilla MF, Selva L, Gene A, Pallares R. Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. *J Infect* 2009; 59: 75–82.
16. Chiou A, Sgambatti S, Almeida SC, Cobo R, Andrade AL, De Cunto MC. Molecular assessment of invasive *Streptococcus pneumoniae* serotype 1 in Brazil: evidence of clonal replacement. *J Med Microbiol* 2008; 57: 839–844.
17. Marimon JM, Ercibengoa M, Alonso M, Zubizarreta M, Pe' rez-Trallero E. Clonal structure and 21-year evolution of *Streptococcus pneumoniae* serotype 1 isolates in northern Spain. *Clin Microbiol Infect* 2009; 15: 875–877.
18. Nunes S, Sa' -Lea' o R, Pereira LC, Lencastre H. Emergence of a serotype 1 *Streptococcus pneumoniae* lineage colonising healthy children in

Portugal in the seven-valent conjugate vaccination era. *Clin Microbiol Infect* 2008; 14: 82–84.

19. Mart'ın A, Ishrat H, Timothy A et al. Seasonality and outbreak of a predominant *Streptococcus pneumoniae* serotype 1 clone from the Gambia: expansion of ST217 hypervirulent clonal complex in West Africa. *BMC Microbiol* 2008; 8: 198.

©2011 The Authors

Outbreak of KPC-3-producing, and colistin-resistant, *Klebsiella pneumoniae* infections in two Sicilian hospitals

M. L. Mezzatesta¹, F. Gona¹, C. Caio¹, V. Petrolito¹, D. Sciortino¹, A. Sciacca², C. Santangelo³ and S. Stefani¹ 1) Department of Bio-Medical Sciences, Section of Microbiology, University of Catania, 2) University Hospital and 3) Vittorio Emanuele Hospital, Catania, Italy

Abstract

We report the first outbreak caused by colistin-resistant *Klebsiella pneumoniae* producing KPC-3 carbapenamase in two Italian hospitals. This spread occurred in 1 month, and was caused by eight colistin-resistant and carbapenem-resistant *Klebsiella pneumoniae* isolates from eight patients. A further three isolates were obtained from the intestinal tract and pharyngeal colonization. All isolates were multidrug-resistant (MDR), including being resistant to colistin, but they were susceptible to gentamicin and tigecycline. PCR detection showed that all isolates harboured the bla_{KPC-3} gene associated with bla_{SHV-11}, bla_{TEM-1} and bla_{OXA-9}. All *K. pneumoniae* isolates, genotyped by pulsed-field gel electrophoresis and multilocus sequence typing, belonged to the same sequence type (ST)258 clone. From our data and a review of the international literature, *K. pneumoniae* ST258 seems to be the most widespread genetic background for KPC dissemination in Europe.

Keywords: Colistin resistance, colonization, *Klebsiella pneumoniae*, KPC-3, ST258

Original Submission: 8 February 2011; Revised
Submission: 6 April 2011; Accepted: 22 April 2011
Editor: R. Canto'n
Article published online: 7 May 2011

Clin Microbiol Infect 2011; 17: 1444–1447
10.1111/j.1469-0691.2011.03572.x

Corresponding author: M. L. Mezzatesta, Department of
Bio-Medical Sciences (Section of Microbiology), University of Catania,
Via Androne 81, 95124 Catania, Italy
E-mail: mezzate@unict.it

CMI

Clinical Microbiology and Infection ©2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1435–1447

Among class A carbapenemases, KPC enzymes have eclipsed all other major groups i.e. GES, SME, IMI and NMC-A, to become the dominant enzymes, with endemic behaviour and/or outbreaks in 27 states in the USA, as well as in China, South America and Israel [1–5]. Since 2005, KPC-positive strains have been isolated in Europe: in France, Germany, the UK, Greece and, more recently, Italy [6–10].

Until very recently, KPC enzymes had only been found in Enterobacteriaceae; however, they have now been characterized from *Pseudomonas aeruginosa* [11,12] and from several *Acinetobacter* spp. strains [13].

In 2009–2010 in Italy, a few reports outlined the isolation of two KPC variants, i.e. multidrug-resistant (MDR) KPC-2 and KPC-3, belonging to ST258, and susceptible only to colistin, tigecycline and gentamicin [14,15].

We report a hospital outbreak, occurring between 19 August and 27 October 2010, caused by eight colistin-resistant and carbapenem-resistant *Klebsiella pneumoniae* isolates from eight patients in two different hospitals in Catania (University and Vittorio Emanuele hospitals). A further three isolates were obtained from the intestinal tract and pharyngeal colonization of three patients: these strains were included in the study for their characterization.

The first KPC-producing *K. pneumoniae* isolate was obtained from abdominal drainage fluid of a patient aged 84 years admitted to the intensive-care unit (ICU) of the University Hospital and coming from another Sicilian hospital. It was not

possible to establish whether patient 1 could be considered the index case, because an active surveillance culture system was not in place at the time of admission. In the month after the first isolate had been obtained, there was a rapid intrahospital outbreak of these strains isolated from seven patients in different wards (ICU, surgery, internal medicine, transplant unit and paediatric haematology).

Research Notes 1445

Subsequently, after 20 days, one case of bloodstream infection in the nephrology ward of Vittorio Emanuele Hospital occurred, in one patient coming from the ICU of the University Hospital, where three other cases were previously confirmed.

The rapid spread of *K. pneumoniae* with this MDR resistance pattern in such a short period caused concern, and activated an investigation to determine the possible source of this outbreak, to establish the increasing risk of transmission, and to start the infection containment procedure.

In fact, infection control measures, including undertaking contact precautions, segregating infected/colonized patients, and using dedicated staff and equipment as much as possible, were implemented at that time [16].

Therefore, all patients included in our study, after infection, were screened weekly for colonization, by the use of pharyngeal and rectal swabs, with a previously published method in which the culture was grown in the presence of a 10-Ig disk of imipenem and subsequently plated on MacConkey agar [17]: only three of eight patients were colonized, but it was not possible to establish whether they were colonized at the time of admission. The patients remained colonized until discharge. In all cases, targeted combination treatment, including gentamicin plus tigecycline and/or carbapenems and/or an anti-Gram-positive drug, was used. With regard to the outcomes, seven patients are still alive, and one died from causes not related to the infection.

The identification and antimicrobial susceptibility testing of 11 isolates was preliminarily performed with the Vitek 2 system (bioMerieux, Marcy l'Etoile, France). The identified species level was centrally reconfirmed with the API 20E system (Bio Merieux), and the MICs were determined with a microdilution method, interpreted according to EUCAST guidelines [18]. These isolates were resistant to almost all antibiotics, including colistin (MIC 64 mg/L)

TABLE 1. Clinical characteristics of patients and antibiotic susceptibility of KPC-3-producing *Klebsiella pneumoniae*

| Patients | Date | Hospital | Ward | Specimens | MIC (mg/L) | | | | | | | | | | | |
|----------------|-------------------|------------|------------------------|--------------------|------------|------|-----|------|------|------|-----|------|----|----|-----|----|
| | | | | | IPM | MEM | DOR | ETP | CEF | CAZ | CTX | TZP | TG | CT | CIP | GM |
| 1 | 19 August 2010 | University | ICU | Abdominal drainage | 32 | 64 | 64 | >128 | 128 | >64 | >64 | >512 | 1 | 16 | 128 | 2 |
| 2 | 31 August 2010 | University | Surgery | CVC | 64 | 64 | 64 | >128 | >128 | >64 | >64 | >512 | 1 | 32 | 128 | 2 |
| 3 | 10 September 2010 | University | ICU | Bloodstream | 64 | 128 | 64 | 128 | >128 | >64 | >64 | >512 | 1 | 16 | 128 | 2 |
| 4 | 19 September 2010 | University | ICU | Bronchial aspirate | 64 | 64 | 32 | >128 | >128 | >64 | >64 | >512 | 1 | 32 | 128 | 2 |
| 5 | 20 September 2010 | University | Internal Medicine | Urine | 64 | 64 | 64 | >128 | >128 | >64 | >64 | >512 | 1 | 8 | 256 | 2 |
| 6 | 23 September 2010 | University | Transplant | Sputum | 32 | 64 | 128 | 128 | 128 | >64 | >64 | >512 | 1 | 64 | 128 | 2 |
| 7 | 26 September 2010 | University | Paediatric Haematology | Bloodstream | 64 | 64 | 256 | >128 | 128 | >64 | >64 | >512 | 1 | 32 | 128 | 2 |
| 8 | 19 October 2010 | VE | Nephrology | Bloodstream | 128 | 512 | 64 | 512 | 512 | >512 | 256 | >512 | 1 | 8 | 256 | 2 |
| 3 _a | 20 October 2010 | University | ICU | Pharyngeal swab | 32 | 64 | 64 | 128 | 128 | >64 | >64 | >512 | 1 | 32 | 128 | 2 |
| 7 _a | 26 October 2010 | University | Paediatric Haematology | Rectal swab | >512 | >512 | 64 | >512 | 256 | >512 | 256 | >512 | 1 | 8 | 128 | 2 |
| 4 _a | 27 October 2010 | University | ICU | Rectal swab | 64 | 512 | 64 | 512 | 512 | >512 | 256 | >512 | 1 | 16 | 128 | 2 |

IPM, imipenem; MEM, meropenem; DOR, doripenem; ETP, ertapenem; CEF, cefepime; CAZ, ceftazidime; CTX, cefotaxime; TZP, piperacillin-tazobactam; TG, tigecycline; CT, colistin; CIP, ciprofloxacin; GM, gentamicin; VE, Vittorio Emanuele; CVC, central venous catheter; ICU, intensive-care unit.

^a Colonization.

©2011 The Authors Clinical Microbiology and Infection ©2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1435–1447

1446 Clinical Microbiology and Infection, Volume 17 Number 9, September 2011

CMI

and carbapenems. All isolates were susceptible only to tigecycline (MIC 1 mg/l) and gentamicin (MIC 2 mg/L); see Table 1.

Analysis of b-lactamase genes by PCR and sequencing revealed the presence of bla_{KPC-3}, bla_{SHV-11}, bla_{TEM-1} and bla_{OXA-9} in all isolates, whereas genes encoding other enzymes (CTX type and VIM type) were not detected.

All *K. pneumoniae* isolates, genotyped after XbaI digestion by pulsed-field gel electrophoresis, belonged to the same clone, as they were indistinguishable from each other (100% identity) according to the criteria described previously by Tenover et al. [19], and with the multilocus sequence typing (MLST) scheme, according to the protocol described on the *K. pneumoniae* MLST website (<http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html>) [20], all isolates were attributed to sequence type (ST)258.

This study reports, for the first time, an outbreak of KPC-3 colistin-resistant *K. pneumoniae* infection in Italy. However, in our country, there are only a few reports on KPC isolation (all colistin-susceptible). The first case detected was from an inpatient with a complicated intraabdominal infection in 2009 [10]; subsequently, KPC-3 *K. pneumoniae* ST258 was found in Palermo [14] in 13 patients. Another isolate of KPC *K. pneumoniae* was identified in Rome, but the strain was not characterized [15], and a KPC-2 *K. pneumoniae* isolate was characterized in Switzerland from a Sicilian patient [21]. In all but one of these cases, the strains were ST258, and were susceptible to gentamicin, tigecycline and colistin.

Our isolates were colistin-resistant KPC-3 ST258 *K. pneumoniae*; colistin resistance is still uncommon among KPC producers (an outbreak of KPC-2 ST258 was recently described in Greece), and has been attributed mainly to the modification of lipid A of the outer membrane and the presence of an efflux pump [22,23]. In our study, the exact mechanism of colistin resistance was not investigated.

Even though, in our cases, all patients were cured, we observed that three of them tended to remain colonized until their discharge. It was not possible to continue the surveillance of these patients after their discharge from hospital. The other five patients were negative for all of the surveillance time.

All of these observations, together with the awareness of the limited therapeutic options for treatment these infections, lead to the alarming conclusion that we need urgent action to slow down and control the worldwide and epidemic spread of carbapenamase-producing Enterobacteriaceae resistant to colistin, which is one of the few drugs active against MDR Gram-negative bacteria.

©2011 The Authors

Acknowledgements

The authors thank G. Rossolini for providing the strain *K. pneumoniae* FIPP 1 used as a control.

Transparency Declaration

This work was supported by MIUR funding no. 2007SCA9RK to S. Stefani. None of the authors have a commercial or other association that might pose a conflict of interest.

References

1. Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenems hydrolyzing b-lactamase KPC-1 from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2001; 45: 1151–1161.

2. Woodford N, Tierno PM Jr, Young K et al. Outbreak of *Klebsiella pneumoniae* producing a new carbapenem-hydrolyzing class A β lactamase, KPC-3, in a New York medical center. *Antimicrob Agents Chemother* 2004; 48: 4793–4799.
3. Villegas MV, Lolans K, Correa A et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of *Klebsiella pneumoniae* from South America. *Antimicrob Agents Chemother* 2006; 50: 2880–2882.
4. Cai JC, Zhou HW, Zhang R, Chen GX. Emergence of *Serratia marcescens*, *Klebsiella pneumoniae*, and *Escherichia coli* isolates possessing the plasmid-mediated carbapenem-hydrolyzing β -lactamase KPC-2 in intensive care units of a Chinese hospital. *Antimicrob Agents Chemother* 2008; 52: 2014–2018.
5. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant *Klebsiella pneumoniae* strains in an Israeli hospital. *Antimicrob Agents Chemother* 2007; 51: 3026–3029.
6. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing β -lactamase KPC in a *Klebsiella pneumoniae* isolate from France. *Antimicrob Agents Chemother* 2005; 49: 4423–4424.
7. Wendt C, Schu`tt S, Dalpke AH et al. First outbreak of *Klebsiella pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae* in Germany. *Eur J Clin Microbiol Infect Dis* 2010; 29: 563–570.
8. Woodford N, Zhang J, Warner M et al. Arrival of *Klebsiella pneumoniae* producing KPC carbapenemase in the United Kingdom. *J Antimicrob Chemother* 2008; 62: 1261–1264.
9. Tsakris A, Kristo I, Poulou A, Markou F, Ikonomidis A, Pournaras S. First occurrence of KPC-2-possessing *Klebsiella pneumoniae* in a Greek hospital and recommendation for detection with boronic acid disc tests. *J Antimicrob Chemother* 2008; 62: 1257–1260.
10. Giani T, D'Andrea MM, Pecile P et al. Emergence in Italy of *Klebsiella pneumoniae* sequence type 258 producing KPC-3 carbapenemase. *J Clin Microbiol* 2009; 47: 3793–3794.
11. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of *Pseudomonas aeruginosa* isolates producing a KPC-type carbapenem-hydrolyzing β -lactamase. *Antimicrob Agents Chemother* 2007; 51: 1553–1555.
12. Poirel L, Nordmann P, Lagrutta E, Cleary T, Munoz-Price LS. Emergence of KPC producing *Pseudomonas aeruginosa* in the United States. *Antimicrob Agents Chemother* 2010; 54: 3072.
19. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis criteria for bacterial strain typing. *J Clin Microbiol* 1995; 33: 2233–2239.
20. Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus sequence typing of *Klebsiella pneumoniae* nosocomial isolates. *J Clin Microbiol* 2005; 43: 4178–4182.
21. Poirel L, Lienhard R, Potron A, Malinverni R, Siegrist HH, Nordmann P. Plasmid-mediated carbapenem-hydrolyzing β -lactamase KPC-2 in a *Klebsiella pneumoniae* isolate from Switzerland. *J Antimicrob Chemother* 2011; 66: 675–676.
22. Kontopoulou K, Protonotariou E, Vasilakos K et al. Hospital outbreak caused by *Klebsiella pneumoniae* producing KPC-2 β -lactamase resistant to colistin. *J Hosp Infect* 2010; 76: 70–73.
23. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. *Clin Microbiol Rev* 2008; 21: 449–465.

CMI

Clinical Microbiology and Infection ©2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1435–1447

13. Robledo IE, Aquino EE, Sante MI et al. Detection of KPC in *Acinetobacter* spp in Puerto Rico. *Antimicrob Agents Chemother* 2010; 54: 1354–1357.
14. Mammina C, Palma DM, Bonura C et al. Outbreak of infection with *Klebsiella pneumoniae* Sequence Type 258 producing *Klebsiella pneumoniae* carbapenemase 3 in an intensive care unit in Italy. *J Clin Microbiol* 2010; 48: 1506–1507.
15. Fontana C, Favaro M, Sarmati L et al. Emergence of KPC-producing *Klebsiella pneumoniae* in Italy. *BMC Res Notes* 2010; 23: 3–40.
16. Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase producing Enterobacteriaceae in acute care facilities. *MMWR* 2009; 58: 256–260.
17. Landman D, Salvani JK, Bratu S, Quale J. Evaluation of techniques for detection of carbapenem-resistant *Klebsiella pneumoniae* in stool surveillance cultures. *J Clin Microbiol* 2005; 43: 5639–5641.
18. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 13. Basel: EUCAST, January 2011.

